Our results indicate that, together with mutation and gene expression signatures, miRNA expression analysis may aid in evaluating the competency of homologous recombination, and thus eventually increase the ability to predict response to PARPi, in order to ultimately identify additional breast cancer patients eligible for PARP-inhibition including regimens. The gene discussed is PARP1; the disease is breast carcinoma.